Yuko Palesch to Treatment Outcome
This is a "connection" page, showing publications Yuko Palesch has written about Treatment Outcome.
Connection Strength
1.318
-
Power and sample size simulations for Randomized Play-the-Winner rules. Contemp Clin Trials. 2007 Jul; 28(4):487-99.
Score: 0.122
-
Statistical analysis plan for pooled individual patient data from two landmark randomized trials (INTERACT2 and ATACH-II) of intensive blood pressure lowering treatment in acute intracerebral hemorrhage. Int J Stroke. 2019 04; 14(3):321-328.
Score: 0.069
-
Treatment effect on ordinal functional outcome using piecewise multistate Markov model with unobservable baseline: an application to the modified Rankin scale. J Biopharm Stat. 2019; 29(1):82-97.
Score: 0.067
-
Twelve-Month Clinical and Quality-of-Life Outcomes in the Interventional Management of Stroke III Trial. Stroke. 2015 May; 46(5):1321-7.
Score: 0.054
-
A surrogate-primary replacement algorithm for response-adaptive randomization in stroke clinical trials. Stat Methods Med Res. 2017 Jun; 26(3):1078-1092.
Score: 0.053
-
Regression analysis of ordinal stroke clinical trial outcomes: an application to the NINDS t-PA trial. Int J Stroke. 2014 Feb; 9(2):226-31.
Score: 0.048
-
Covariate imbalance and adjustment for logistic regression analysis of clinical trial data. J Biopharm Stat. 2013; 23(6):1383-402.
Score: 0.046
-
Impact of safety monitoring on error probabilities of binary efficacy outcome analyses in large phase III group sequential trials. Pharm Stat. 2012 Jul-Aug; 11(4):310-7.
Score: 0.044
-
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011 Dec; 15(3):559-76.
Score: 0.043
-
The Albumin in Acute Stroke Part 1 Trial: an exploratory efficacy analysis. Stroke. 2011 Jun; 42(6):1621-5.
Score: 0.041
-
Quantifying the cost in power of ignoring continuous covariate imbalances in clinical trial randomization. Contemp Clin Trials. 2011 Mar; 32(2):250-9.
Score: 0.040
-
Comments regarding the recent OAST article. Stroke. 2008 Jan; 39(1):e14; author reply e15.
Score: 0.032
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006 Aug; 37(8):2107-14.
Score: 0.029
-
Applying a phase II futility study design to therapeutic stroke trials. Stroke. 2005 Nov; 36(11):2410-4.
Score: 0.028
-
A randomized, placebo-controlled trial of buspirone for the treatment of anxiety in opioid-dependent individuals. Am J Addict. 2004 Jan-Feb; 13(1):53-63.
Score: 0.025
-
J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke. 2022 12; 17(10):1129-1136.
Score: 0.021
-
Intensive blood pressure lowering with nicardipine and outcomes after intracerebral hemorrhage: An individual participant data systematic review. Int J Stroke. 2022 06; 17(5):494-505.
Score: 0.021
-
Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage. Neurology. 2021 02 02; 96(5):e740-e751.
Score: 0.020
-
Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2. Stroke. 2020 08; 51(8):2282-2286.
Score: 0.019
-
Late Neurological Deterioration after Acute Intracerebral Hemorrhage: A post hoc Analysis of the ATACH-2 Trial. Cerebrovasc Dis. 2020; 49(1):26-31.
Score: 0.019
-
Assessment of the End Point Adjudication Process on the Results of the Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: A Secondary Analysis. JAMA Netw Open. 2019 09 04; 2(9):e1910769.
Score: 0.018
-
Blood pressure control and clinical outcomes in acute intracerebral haemorrhage: a preplanned pooled analysis of individual participant data. Lancet Neurol. 2019 09; 18(9):857-864.
Score: 0.018
-
Association of Very Early Serum Levels of S100B, Glial Fibrillary Acidic Protein, Ubiquitin C-Terminal Hydrolase-L1, and Spectrin Breakdown Product with Outcome in ProTECT III. J Neurotrauma. 2019 10 15; 36(20):2863-2871.
Score: 0.018
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
Score: 0.018
-
Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. Ann Neurol. 2019 01; 85(1):105-113.
Score: 0.017
-
The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods. Int J Stroke. 2019 02; 14(2):207-214.
Score: 0.017
-
Blood Pressure-Attained Analysis of ATACH 2 Trial. Stroke. 2018 06; 49(6):1412-1418.
Score: 0.017
-
Prehospital Intubation is Associated with Favorable Outcomes and Lower Mortality in ProTECT III. Prehosp Emerg Care. 2017 Sep-Oct; 21(5):539-544.
Score: 0.016
-
Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III. J Am Heart Assoc. 2017 May 08; 6(5).
Score: 0.016
-
A multicenter randomized controlled trial of endovascular therapy following imaging evaluation for ischemic stroke (DEFUSE 3). Int J Stroke. 2017 10; 12(8):896-905.
Score: 0.015
-
Power of logrank test and Cox regression model in clinical trials with heterogeneous samples. Stat Med. 1997 Mar 15; 16(5):583-97.
Score: 0.015
-
Intensive Blood-Pressure Lowering in Cerebral Hemorrhage. N Engl J Med. 2016 12 08; 375(23):e48.
Score: 0.015
-
Endovascular Therapy of M2 Occlusion in IMS III: Role of M2 Segment Definition and Location on Clinical and Revascularization Outcomes. AJNR Am J Neuroradiol. 2017 Jan; 38(1):84-89.
Score: 0.015
-
ALIAS (Albumin in Acute Ischemic Stroke) Trials: Analysis of the Combined Data From Parts 1 and 2. Stroke. 2016 09; 47(9):2355-9.
Score: 0.015
-
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016 09 15; 375(11):1033-43.
Score: 0.015
-
Very Early Administration of Progesterone Does Not Improve Neuropsychological Outcomes in Subjects with Moderate to Severe Traumatic Brain Injury. J Neurotrauma. 2017 01 01; 34(1):115-120.
Score: 0.014
-
Effect of endovascular reperfusion in relation to site of arterial occlusion. Neurology. 2016 Feb 23; 86(8):762-70.
Score: 0.014
-
Endovascular Therapy Is Effective and Safe for Patients With Severe Ischemic Stroke: Pooled Analysis of Interventional Management of Stroke III and Multicenter Randomized Clinical Trial of Endovascular Therapy for Acute Ischemic Stroke in the Netherlands Data. Stroke. 2015 Dec; 46(12):3416-22.
Score: 0.014
-
Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis. Stroke. 2015 Feb; 46(2):461-4.
Score: 0.013
-
Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the Interventional Management of Stroke III trial. Radiology. 2014 Oct; 273(1):202-10.
Score: 0.013
-
Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):567-74.
Score: 0.013
-
Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. Stroke. 2014 May; 45(5):1408-14.
Score: 0.013
-
Collaterals at angiography and outcomes in the Interventional Management of Stroke (IMS) III trial. Stroke. 2014 Mar; 45(3):759-64.
Score: 0.012
-
Alberta Stroke Program early computed tomography score to select patients for endovascular treatment: Interventional Management of Stroke (IMS)-III Trial. Stroke. 2014 Feb; 45(2):444-9.
Score: 0.012
-
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol. 2013 Nov; 12(11):1049-58.
Score: 0.012
-
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
Score: 0.012
-
Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012 Feb 16; 366(7):591-600.
Score: 0.011
-
Flexible analytical methods for adding a treatment arm mid-study to an ongoing clinical trial. J Biopharm Stat. 2012; 22(4):758-72.
Score: 0.011
-
Strokes with minor symptoms: an exploratory analysis of the National Institute of Neurological Disorders and Stroke recombinant tissue plasminogen activator trials. Stroke. 2010 Nov; 41(11):2581-6.
Score: 0.010
-
Effect of systolic blood pressure reduction on hematoma expansion, perihematomal edema, and 3-month outcome among patients with intracerebral hemorrhage: results from the antihypertensive treatment of acute cerebral hemorrhage study. Arch Neurol. 2010 May; 67(5):570-6.
Score: 0.010
-
Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis. Stroke. 2010 Apr; 41(4):732-8.
Score: 0.009
-
The impact of loss to follow-up on hypothesis tests of the treatment effect for several statistical methods in substance abuse clinical trials. J Subst Abuse Treat. 2009 Jul; 37(1):54-63.
Score: 0.009
-
Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol. 2008 Mar; 29(3):582-7.
Score: 0.008
-
The ALIAS (ALbumin In Acute Stroke) Phase III randomized multicentre clinical trial: design and progress report. Biochem Soc Trans. 2006 Dec; 34(Pt 6):1323-6.
Score: 0.008
-
Using the baseline CT scan to select acute stroke patients for IV-IA therapy. AJNR Am J Neuroradiol. 2006 Sep; 27(8):1612-6.
Score: 0.007
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke. 2006 Aug; 37(8):2100-6.
Score: 0.007